CTOs on the Move


 
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.egalet.com
  • 600 Lee Road Suite 100
    Wayne, PA USA 19087
  • Phone: 610.833.4200

Executives

Name Title Contact Details

Similar Companies

CuraScript

CuraScript is one of the nation's largest providers of specialty injectable and oral medications. CuraScript has been in the specialty pharmacy business since 1989. Between 1994 and August 1, 2000, the company operated as Coram Prescription Services

Koneksa Health

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries.

Pathalys

Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys` initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.

Symphogen

Symphogen, Inc. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.